for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akari Therapeutics PLC (ADR)

AKTX.O

Latest Trade

1.43USD

Change

0.01(+0.70%)

Volume

121,342

Today's Range

1.42

 - 

1.48

52 Week Range

1.32

 - 

4.21

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.42
Open
1.48
Volume
121,342
3M AVG Volume
2.24
Today's High
1.48
Today's Low
1.42
52 Week High
4.21
52 Week Low
1.32
Shares Out (MIL)
4,759.73
Market Cap (MIL)
75.27
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Akari Therapeutics Reports Third Quarter 2021 Financial Results And Highlights Recent Clinical Progress

Akari Therapeutics PLC Reports Q2 2021 Financial Results

Akari Therapeutics Says Company Had Cash Of About $6.7 Million, Compared To Cash Of About $14.1 Million At December 31, 2020

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akari Therapeutics PLC (ADR)

Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company. The Company is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid or leukotriene system and the bioamine system for the treatment of rare and orphan diseases. Its lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4 (LTB4). It inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement. It inhibits LTB4 by capturing the fatty acid within the body of the nomacopan protein. The anaphylatoxin (C5a) and the membrane attack complex (MAC) cause and maintain a proinflammatory and prothrombotic state. LTB4 also activates cells via two separate GPCRs and can independently cause and maintain a proinflammatory state.

Industry

Biotechnology & Drugs

Contact Info

24 W 40th St Fl 8

NEW YORK, NY

10018-1028

United States

+1.646.3500702

http://akaritx.com/

Executive Leadership

Ray Prudo

Executive Chairman of the Board

Clive Richardson

Chief Executive Officer, Chief Operating Officer, Director

Torsten Hombeck

Chief Financial Officer

Michael Grissinger

Director

David Byrne

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
6.07
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-227.58
Return on Equity (TTM)
-129.93

Latest News

Latest News

BRIEF-Aspire Capital Fund Reports 19.89% Passive Stake In Akari Therapeutics - SEC Filing

* ASPIRE CAPITAL FUND LLC REPORTS 19.89% PASSIVE STAKE IN AKARI THERAPEUTICS PLC AS OF JULY 1 - SEC FILING Source text for Eikon: https://bit.ly/3eT7bFx Further company coverage:

BRIEF-Akari Therapeutics Appoints Chief Financial Officer

* AKARI THERAPEUTICS ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

BRIEF-Akari Therapeutics Enters Into A Securities Purchase Agreement For Up To $30 Mln With Aspire Capital Fund

* AKARI THERAPEUTICS ENTERS INTO A SECURITIES PURCHASE AGREEMENT FOR UP TO $30 MILLION WITH ASPIRE CAPITAL FUND, LLC

BRIEF-Akari Therapeutics Reports Qtrly Loss Per Share $0.00

* AKARI THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS

BRIEF-Akari Therapeutics Receives Positive EMA Opinion On Orphan Designation For Nomacopan For Bullous Pemphigoid

* AKARI THERAPEUTICS RECEIVES POSITIVE EMA OPINION ON ORPHAN DESIGNATION FOR NOMACOPAN FOR BULLOUS PEMPHIGOID

BRIEF-Akari Therapeutics Announces Positive Topline Results From Phase II Study Of Nomacopan In Bullous Pemphigoid Patients

* AKARI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM FULLY RECRUITED PHASE II STUDY OF NOMACOPAN IN BULLOUS PEMPHIGOID PATIENTS

BRIEF-Akari Reports Fourth Quarter Results

* AKARI THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BRIEF-Akari Therapeutics Plc Files Prospectus Relates To Resale, By Selling Shareholders Of Up To 765.6 Million Ordinary Shares

* AKARI THERAPEUTICS PLC FILES PROSPECTUS RELATES TO RESALE, BY SELLING SHAREHOLDERS OF UP TO 765.6 MILLION ORDINARY SHARES - SEC FILING Source text: (https://bit.ly/2UkMRF3) Further company coverage:

BRIEF-Akari Therapeutics Announces Private Placement

* AKARI THERAPEUTICS PLC - WILL ISSUE UNREGISTERED ADSS AT A PURCHASE PRICE OF $1.70 PER ADS Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up